Campaigning for Orkambi in your region
What is Orkambi?
Orkambi is the second such drug to be licensed for use in people with cystic fibrosis, the first was Kalydeco.
- Orkambi treats the F508del mutation, which around 50% of people with CF in the UK have.
- Orkambi is a combination medicine, made up of ivacaftor and lumacaftor. Lumacaftor helps get more proteins to the surface of cells in the body, and ivacaftor helps the chloride channels in the cells to operate more effectively. The combination of these two things helps to keep a healthy balance of salt and water in the organs – particularly the lungs. Orkambi is manufactured by Vertex Pharmaceuticals.
Is Orkambi available in the UK?
- According to the 2014 UK Cystic Fibrosis Registry Report, there are 2,834 people in England, 243 people in Scotland, 118 people in Wales and 101 people in Northern Ireland who could benefit from Orkambi.
- Orkambi has been licensed for use in the UK for people with CF over the age of 12 who have two copies of the F508del mutation. Despite this, the National Institute for Health and Care Excellence (NICE) has rejected its use on the NHS.
- In May 2016, the Scottish Medicines Consortium (SMC) noted that Orkambi was a beneficial treatment.In June 2016, NICE recognised Orkambi as an important treatment.
- Both the SMC and NICE were unable to recommend Orkambi for general use within the NHS/HSCNI on grounds of cost-effectiveness and a lack of long-term data.
- Orkambi is currently only prescribed to people on compassionate grounds. Compassionate use means that Vertex Pharmceuticals provide the drug to people who fulfil a number of criteria. Contact your clinician for more information on compassionate use.
What effect does Orkambi have?
96-week data shows that Orkambi can slow decline in lung function - the main cause of death among people with cystic fibrosis - by 42%. This data was unavailable to NICE when they appraised Orkambi.
Why is Orkambi not available to everyone who needs it?
The processes involved in making drugs available to the people they could help are complicated. Creating and testing a drug like Orkambi is very expensive and a lack of long-term data can make it hard for NICE and the SMC, the bodies that appraises these drugs for use in the NHS/HSCNI, to accurately assess their cost-effectiveness in order to make them available.
What are we doing about it?
Stay up to date with Stopping the Clock, our dedicated campaign to put pressure on the Government, NHS and pharmaceutical companies to ensure these drugs reach the people who need them without delay, or join the campaign and get involved yourself by taking part in a region-specific action below.
Take a look at the list of parliamentarians who have supported the campaign for access to Orkambi.
In your region
Following the roundtable and debate we asked you to contact your MPs to ask them to contact Ian Austin MP to sign a cross-party letter. You can read the letter here, or find out if your MP signed the letter here.
Read the latest update on the Stopping the Clock campaign from Lynsey Beswick, Public Affairs Manager at the Trust.
A cross-party roundtable meeting chaired by Ian Austin MP was held on 28 February to continue discussions with Vertex. 41 MPs attended, which was a testament to everyone who contacted their MP and asked for their support.
We have sent a cross-party letter to Jeremy Hunt, Secretary of State for Health and Department of Health Permanent Secretary, Richard Pengelly, calling for a timely resolution to the ongoing negotiations between Vertex and Health and Social Care Northern Ireland. These letters have been signed by 66 MLAs from a number of different parties.
Read the letters:
We have received a response to our letters from Richard Pengelly, which you can read here:
Following the recent Vertex proposal submission to NHS Scotland the Trust are actively engaging with MSPs around a cross-party letter to the Scottish Health Minster Shona Robison to request a meeting. We will give an update once we know more and advise when to contact your MSP to request that they co-sign the letter.
Following the debate in parliament around access to Orkambi please also write to your Scottish MP to ask them add their signature to a cross-party letter to Ministers drafted by Ian Austin MP. You can also request that your MP engage with their local MSP counterpart to apply pressure in the devolved parliaments.
We released a petition to the Welsh Assembly calling for a resolution to negotiations between NHS Wales and Vertex. We surpassed our 5,000-signature target and the issue of Orkambi was automatically considered for debate by the petitions committee on 23 January and again on 7 March.
The committee decided against a debate on access to Orkambi, but we welcome their decision to take action by writing to the Welsh Cabinet Secretary for Health regarding the current Welsh Government communications with Vertex Pharmaceuticals to establish the progress of discussion, ahead of further potential debates on the issue.
Members of the petitions committee demonstrated an interest in the issue of our petition and recognised the situation as a stalemate which must be addressed. The importance of considering the more recent data available was also raised.
A debate was not chosen as the best course of action at this stage, but in principle the nature of the petition is something that could potentially be debated in the future and we will continue to apply pressure once the Assembly processes have been followed.
For the latest news on our Stopping the Clock campaign and other updates in the CF community, sign up to receive our e-newsletter.